Cancer treatments represented 33 per cent of medicines in all phases of clinical trials in 2023, followed by treatments for infectious diseases (13 per cent) and central nervous system diseases (12 per cent), according to a new report by the Patented Medicine Prices Review Board. It found more than 12,000 new medicines were undergoing clinical […]
Canada’s life and health insurers paid out a record $128 billion in health and retirement benefits last year, up from $114 billion in 2022, according to the Canadian Life and Health Insurance Association’s annual fact book. “The benefits that life and health insurers provide through workplace plans and individual policies contributed significantly to Canadians’ health […]
The 2024 Benefits Canada Healthcare Survey highlighted the perfect storm plan sponsors are facing: trying to strike the right balance between competitive benefits and plan sustainability. It’s something that resonates with the benefits leads of three major Canadian employers, who said during Benefits Canada’s report launch event that benefits utilization and meeting the needs of a […]
In 2023, diabetes medications remained the leading drug category for eligible private insurance claims for the second consecutive year, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 15 million plan members in 2023, found the growing prevalence of diabetes, along with expanded heart failure treatment indications and […]
The 10 highest-cost drugs reimbursed by public drug plans in Canada in the 2021/22 fiscal year were all rare disease treatments with annual treatment costs of more than $250,000, according to a new report by the Patented Medicine Prices Review Board. It found the increased use of high-cost drugs continued to be the main factor […]
While three-quarters (76 per cent) of U.S. employers say they provide coverage of glucagon-like peptide-1 drugs for diabetes management, about a quarter (27 per cent) provide coverage of these drugs for weight loss, according to a new survey by the International Foundation of Employee Benefit Plans. The survey, which polled more than 200 U.S. benefits […]
More than half (54 per cent) of Canadian benefits plan members currently live with at least one diagnosed chronic health condition, according to the 2023 Benefits Canada Healthcare Survey. It found the top current diagnoses were a mental-health condition such as depression or anxiety (18 per cent), high cholesterol (12 per cent), arthritis (12 per […]
The growth of gene and cell therapies are raising significant questions among private payers about who bears the responsibility for the costs of these treatments, says Tim Clarke, president at TC Health Consulting Inc. “One issue is whether this is going to be paid for by public health or if it’s an employer health issue. […]
Specialty drugs are accounting for a slightly smaller portion of the total eligible amount for all drug claims, declining from 33.6 per cent in 2021 to 33.1 per cent in 2022, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 4.6 million plan members in 2022, found the […]
The annual spend per private drug plan member increased by 6.3 per cent in 2022, according to Express Scripts Canada’s annual drug trends report. Across both traditional and specialty drugs, the increase was primarily driven by a 5.4 per cent rise in plan members making a claim, which reversed the trend seen in 2020 and […]